Dublin, April 13, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market" report to their offering. The market size for cancer immunotherapies is expected to grow more than fourfold from $16.9 billion in 2015 to $75.8 billion by 2022, representing a rapid compound annual growth rate (CAGR) of 23.9%.
Over the past few decades cancer immunotherapies have developed into important therapeutic options for some types of cancer. Some of these therapies generally enhance the activity of the body's immune system, while others drive the immune system to target specific cancer cells.
The report states that there are currently 2,037 products in active development in the cancer immunotherapy pipeline, equating to 37% of the entire oncology pipeline, and reflecting the strong interest in this class of therapy in product development. According to the research, several late-stage pipeline drugs, as well as some already marketed drugs, are expected to achieve blockbuster status by the end of the forecast period, while a number of existing blockbuster therapies are forecast to experience strong revenue growth. Established immunotherapies, particularly Revlimid, Opdivo, Keytruda and Gazyva, are set to witness rapid sales growth throughout the forecast period, with Keytruda and Opdivo rising by $7 billion and $9 billion, respectively. Revlimid will experience similar levels of growth, driven by label expansions covering oncology indications, including multiple forms of leukemia and lymphoma. Key Topics Covered: 1 Tables & Figures
2 Introduction 2.1 Therapy Area Introduction 2.2 Epidemiology 2.3 Pathophysiology and Etiology 2.4 Symptoms 2.5 Diagnosis and Disease Staging 2.6 Prognosis 2.7 Treatment 3 Key Marketed Products 3.1 Overview 3.2 Rituxan/MabThera - Roche 3.3 Revlimid (lenalidomide) - Celgene 3.4 Yervoy (ipilimumab) - Bristol-Myers Squibb 3.5 Opdivo (nivolumab) - Bristol-Myers Squibb 3.6 Keytruda (pembrolizumab) - Merck & Co. 3.7 Pomalyst (pomalidomid) - Celgene 3.8 Gardasil/Gardasil 9 (human papillomavirus [types 6, 11, 16, 18] (quadrivalent) vaccine-prophylactic vaccine) - Merck & Co. 3.9 Provenge (sipuleucel-T) - Valeant Pharmaceuticals 3.10 Conclusion 4 Pipeline Landscape Assessment 4.1 Overview 4.2 Pipeline Development Landscape 4.3 Molecular Targets in the Pipeline 4.4 Clinical Trials 4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 4.4.5 Conclusion 4.5 Assessment of Key Pipeline Products 4.5.1 Durvalumab - AstraZeneca 4.5.2 Durvalumab + Tremelimumab - AstraZeneca 4.5.3 Tisagenlecleucel-T (CTL-019) - Novartis 4.5.4 KTE-C19 - Kite Pharma 4.5.5 Avelumab - Merck KGaA/Pfizer 4.5.6 Epacadostat - Incyte Corporation 4.5.7 Conclusion 5 Multi-scenario Market Forecast to 2022 5.1 Overall Market Size 5.2 Generic Penetration 5.3 Revenue Forecast by Molecular Target 5.3.1 Immune-Checkpoint Proteins 5.3.2 Tumor Associated Antigens 5.3.3 Cancer Vaccines 5.3.4 Signal Transduction 5.4 Revenue and Market Share Analysis by Company 5.4.1 Celgene - Revlimid to Maintain Celgene's Position as Market Leader 5.4.2 Bristol-Myers Squibb - Opdivo to Drive Revenue from Cancer Immunotherapies 5.4.3 Roche - Revenue Generated from Cancer Immunotherapies Forecast to Grow due to Tecentriq and Gazyva 5.4.4 Merck & Co. - Keytruda Key to Cancer Immunotherapy Market Growth 5.4.5 AstraZeneca - New Approvals to Mark Entry of AstraZeneca in Cancer Immunotherapy Market 5.4.6 Novartis - Cancer Immunotherapies Constitute Small Proportion of Vast Overall Revenue 5.4.7 Amgen - Innovative Imlygic to Help Generate above $1 Billion from Cancer Immunotherapy Market 5.4.8 Pfizer - Overall Cancer Immunotherapy Revenue to Surpass $1 Billion by 2022 due to PD-L1-Inhibitor Avelumab 5.4.9 Kite Pharma - KTE-C19 CAR to Drive Revenue Growth in Forecast Period 6 Company Analysis and Positioning 6.1 Company Landscape 6.2 Marketed and Pipeline Portfolio Analysis 7 Strategic Consolidations 7.1 Licensing Deals 7.1.1 Deal by Region, Year and Value 7.1.2 Deals by Stage of Development and Value 7.1.3 Deals by Molecule Type, Molecular Target and Value 7.1.4 Table for Licensing Deals Valued above $500m 7.2 Co-development Deals 7.2.1 Deals by Region, Year and Value 7.2.2 Deals by Stage of Development and Value 7.2.3 Deals by Molecule Type, Mechanism of Action and Value 7.2.4 Table for Co-development Deals Valued above $100m 8 Appendix For more information about this report visit http://www.researchandmarkets.com/research/wg...bal_cancer
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Cancer Vaccines
